Back to Search
Start Over
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
- Source :
- Breast, 60, 263-271. Churchill Livingstone, Breast, Vol 60, Iss, Pp 263-271 (2021), Ismail, R K, van Breeschoten, J, Wouters, M W J M, van Dartel, M, van der Flier, S, Reyners, A K L, de Graeff, P, Pasmooij, A M G, de Boer, A, Broekman, K E & Hilarius, D L 2021, ' Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer ', Breast, vol. 60, pp. 263-271 . https://doi.org/10.1016/j.breast.2021.11.013, Breast, 60, 263. Churchill Livingstone, The Breast, 60, 263-271. Churchill Livingstone, The Breast : Official Journal of the European Society of Mastology
- Publication Year :
- 2021
-
Abstract
- Background This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC). Patients and methods Patients with advanced BC treated with palbociclib from 2017 to 2020 were included. The Kaplan-Meier method was used to calculate time to next treatment (TTNT) and overall survival (OS) for patients with or without dose reductions. These clinical outcomes were also compared in subgroup analyses for older patients (≥70 years) and younger patients (<br />Highlights • Palbociclib dose reductions occurred in 33% of the real-world patients. • Dose reductions did not lead to poorer overall survival. • Older patients had more dose reductions, but this did not affect overall survival.
- Subjects :
- Oncology
medicine.medical_specialty
Cancer Research
Early discontinuation
Receptor, ErbB-2
Pyridines
Advanced breast
Breast Neoplasms
Time to next treatment
Palbociclib
Piperazines
Breast cancer
ErbB-2
Older patients
Breast Neoplasms/drug therapy
Internal medicine
Clinical outcomes
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
In patient
RC254-282
Aged
Drug Tapering
business.industry
Cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
General Medicine
Middle Aged
Dose reductions
medicine.disease
Original Article
Female
Surgery
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
business
Receptor
Subjects
Details
- Language :
- English
- ISSN :
- 09609776
- Database :
- OpenAIRE
- Journal :
- Breast, 60, 263-271. Churchill Livingstone, Breast, Vol 60, Iss, Pp 263-271 (2021), Ismail, R K, van Breeschoten, J, Wouters, M W J M, van Dartel, M, van der Flier, S, Reyners, A K L, de Graeff, P, Pasmooij, A M G, de Boer, A, Broekman, K E & Hilarius, D L 2021, ' Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer ', Breast, vol. 60, pp. 263-271 . https://doi.org/10.1016/j.breast.2021.11.013, Breast, 60, 263. Churchill Livingstone, The Breast, 60, 263-271. Churchill Livingstone, The Breast : Official Journal of the European Society of Mastology
- Accession number :
- edsair.doi.dedup.....6669dc6ae2535d502ab173b09ee85cc3